Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 2:01 AM
Ignite Modification Date: 2025-12-25 @ 2:01 AM
NCT ID: NCT02849860
Eligibility Criteria: Key Inclusion Criteria: * Male or female, between the ages of 9 and \<17 years (16 years 11 months inclusive). * Written and oral informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or legal guardian must sign the informed consent. * Subject must have a score of 3 (moderate) to 4 (severe) on the Evaluator's Global Severity Assessment at the screening and baseline visit in the facial area. * Subjects with facial acne inflammatory lesions count no less than 20 but no more than 40. * Subjects with facial acne non-inflammatory lesions count no less than 20 but no more than 100. Key Exclusion Criteria: * Use of investigational drug or device within 30 days of enrollment or participation in research study or concurrent study with this study. * Any dermatological conditions on the face that could interfere with clinical evaluations acne conglobate, acne fulminans, secondary acne, perioral dermatitis, clinical significant rosacea, gram negative folliculitis. * Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive. * Subjects with facial beard or mustache that could interfere with any study assessments.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 9 Years
Maximum Age: 17 Years
Study: NCT02849860
Study Brief:
Protocol Section: NCT02849860